JDRF’s Relationship with Genentech Helps Support Eyesight-Saving Drug
Novartis Pharmaceuticals, through its licensing agreements with Genentech/Roche, recently announced the European approval of a landmark drug known as Lucentis, which helps to reverse the vision loss...
View ArticleLucentis Treatment Shown Effective Against Eye Disease
A groundbreaking study has identified the first new treatment for people with diabetic eye disease in the last 25 years. The study, a Phase II clinical trial, showed that the drug Lucentis combined...
View ArticleEye Disease Treatment Shown Effective
A groundbreaking study has identified the first new treatment for people with diabetic eye disease in the last 25 years. The results show it not only stops the progress of eye disease, but improves...
View ArticleAugust Update
On August 3, JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust, announced the award of a $4.6 million grant to the laboratory of Camillo Ricordi, M.D., of the Diabetes...
View ArticleLucentis for Diabetic Eye Disease
Genentech, Inc., a member of the Roche Group, announced that its second Phase III study known as RISE, which is evaluating the drug Lucentis in patients with diabetic macular edema, met its primary...
View ArticleJDRF Forms New Partnership to Advance Novel Treatment Research for Diabetic...
Building on previous research funded by JDRF, the organization has teamed with KalVista Pharmaceuticals, a company based in the United Kingdom, to continue the quest for therapies that will halt or...
View ArticleJDRF Funds Testing of New Drug for Diabetic Macular Edema
In 2011, Lucentis became the first breakthrough treatment in more than 20 years for people with diabetic macular edema (DME), a leading cause of blindness among the working-age population (ages 20 to...
View ArticleJDRF Discusses New Treatment for Diabetic Eye Disease
Eye disease is one of the most common complications of type 1 diabetes. Eye disease in people with diabetes, also known as diabetic retinopathy, is caused by chronic high blood sugar levels, which can...
View ArticleFDA Approves Lucentis to Treat Diabetic Macular Edema
For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis...
View Article
